. . . . . "sertraline" . . . "obsessive-compulsive disorder" . . . . . . "Sertraline has shown efficacy and safety at doses of 50-200 mg/day [72] in treating phobic-related states, with a greater reduction in symptoms related to anxiety/fear, physical symptoms and avoidance behaviors [73]. Clinical improvements in obsessive symptoms and phobic behavior have been achieved with long-term therapy, with a good tolerability profile. A rapid sertraline titration up to 200 mg/day correlated with fast response rates. A 20-week study with sertraline 50-200 mg/day produced significant improvements both in functioning and social skills [74]. Stable sertraline treatment guaranteed lower recurrence rates, and a general improvement in quality of life. Placebo-controlled studies consistently showed sertraline-related treatment response [72, 75, 76], although with one exception [77]. Treatment of refractory OCD with high doses of sertraline (250-400 mg/day) resulted in a significant symptom improvement and a similar rate of adverse events observed with a 200 mg/day dose [78]." . . . . . . . "adults" . . . "RSA" . "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCR9fz0fKCdWOWC+pxhkQhEM/ppbdIYe5TLSdj+lJzSlv9mYBaPgrzVezSwwbmhlHBPDZa4/vHycU315BdmUGq+pXllp9+rWFfrb+kBJwhZjpG6BeyyXBsRFz4jmQVxl/ZYHilQTh/XalYzKkEAyTiEMPee4Kz61PaWOKH24CsnOQIDAQAB" . "M7gktdbiNUgTK9MQ2fCjlG/ldf2/3FUNLKyY44iK8dgCUk1BtoZyE/3UjniS47B1kyn26A1ZK3GuJpZNespnWE32XB5m9b9lWhYhus1sDOtoc7hKqZH7Dz045S95TwJCr1s9hbEVs3ZM7rhVpsiv8utyodP/Yl+E3enS9DLotGM=" . . "2022-09-16T11:53:49.145453"^^ . . . "2.3.0" .